[HTML][HTML] Monoclonal antibody therapies against SARS-CoV-2

D Focosi, S McConnell, A Casadevall… - The Lancet Infectious …, 2022 - thelancet.com
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

[HTML][HTML] SARS-CoV-2: a master of immune evasion

A Rubio-Casillas, EM Redwan, VN Uversky - Biomedicines, 2022 - mdpi.com
Viruses and their hosts have coevolved for a long time. This coevolution places both the
pathogen and the human immune system under selective pressure; on the one hand, the …

[HTML][HTML] Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu… - Nature, 2022 - nature.com
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

[HTML][HTML] Antibody evasion properties of SARS-CoV-2 Omicron sublineages

S Iketani, L Liu, Y Guo, L Liu, JFW Chan, Y Huang… - Nature, 2022 - nature.com
The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …

[HTML][HTML] Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

W He, R Musharrafieh, G Song, K Dueker, LV Tse… - Nature …, 2022 - nature.com
The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into …

[图书][B] Combatting a continuously evolving pathogen, SARS-CoV-2

S Iketani - 2022 - search.proquest.com
Abstract The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic has
led to widespread socioeconomic and clinical damage. The coalescent response from the …